225 results on '"Mattison DR"'
Search Results
2. Risk of Motor-Vehicle Accidents Increases with Multimorbidity
- Author
-
Fortin, Y, primary, Crispo, JA, additional, McNair, DS, additional, Cohen, D, additional, Dahrouge, S, additional, Mattison, DR, additional, and Krewski, D, additional
- Published
- 2016
- Full Text
- View/download PDF
3. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial
- Author
-
Koren, G, Clark, S, Hankins, GDV, Caritis, SN, Umans, JG, Miodovnik, M, Mattison, DR, Matok, I, Koren, G, Clark, S, Hankins, GDV, Caritis, SN, Umans, JG, Miodovnik, M, Mattison, DR, and Matok, I
- Abstract
Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo. Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing. Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement. Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy. Trial Registration: Clinical Trial Registration No: NCT00614445.
- Published
- 2015
4. PCV25 - Proton Pump Inhibitors and Major Adverse Cardiovascular Outcomes: A Systematic Review
- Author
-
Farhat, N, Fortin, Y, Birkett, N, Mattison, DR, and Krewski, D
- Published
- 2016
- Full Text
- View/download PDF
5. PHS149 - Risk of Motor-Vehicle Accidents Increases with Multimorbidity
- Author
-
Fortin, Y, Crispo, JA, McNair, DS, Cohen, D, Dahrouge, S, Mattison, DR, and Krewski, D
- Published
- 2016
- Full Text
- View/download PDF
6. Are We Optimizing Gestational Diabetes Treatment With Glyburide? The Pharmacologic Basis for Better Clinical Practice
- Author
-
Hebert, MF, primary, Ma, X, additional, Naraharisetti, SB, additional, Krudys, KM, additional, Umans, JG, additional, Hankins, GDV, additional, Caritis, SN, additional, Miodovnik, M, additional, Mattison, DR, additional, Unadkat, JD, additional, Kelly, EJ, additional, Blough, D, additional, Cobelli, C, additional, Ahmed, MS, additional, Snodgrass, WR, additional, Carr, DB, additional, Easterling, TR, additional, and Vicini, P, additional
- Published
- 2009
- Full Text
- View/download PDF
7. Adolescents in Clinical Trials
- Author
-
Kapogiannis, BG, primary and Mattison, DR, additional
- Published
- 2008
- Full Text
- View/download PDF
8. Environmental exposures and development.
- Author
-
Mattison DR and Mattison, Donald R
- Published
- 2010
- Full Text
- View/download PDF
9. Asthma-related medication use among children in the United States.
- Author
-
Korelitz JJ, Zito JM, Gavin NI, Masters MN, McNally D, Irwin DE, Kelleher K, Bethel J, Xu Y, Rubin J, and Mattison DR
- Published
- 2008
- Full Text
- View/download PDF
10. Prediction of risk for human developmental toxicity: How important are animal studies for hazard identification?
- Author
-
Jelovsek, FR, primary, Mattison, DR, additional, and Chen, JJ, additional
- Published
- 1990
- Full Text
- View/download PDF
11. Preparing your practice for a disaster.
- Author
-
Mattison DR, Leavitt R, Landesman LY, and Rosenfield A
- Abstract
The events of September 11 have heightened the need for disaster-planning in the health-care setting. Because women are among those most vulnerable to the health impact of disasters, ob/gyns have a unique responsibility to be prepared for the worst. [ABSTRACT FROM AUTHOR]
- Published
- 2002
12. Knowledge and Use of Folic Acid by Women of Childbearing Age--United States, 1995 and 1998.
- Author
-
Petrini, JR, Damus, K, Johnston, RB, and Mattison, DR
- Subjects
WOMEN'S health ,FOLIC acid ,TELEPHONE surveys ,NEURAL tube defect prevention - Abstract
Reports on a study on folic acid knowledge and practices among women of childbearing age in the United States from 1995 to 1998. Details on the Gallup telephone survey; Results; Campaign for the prevention of neural tube defects.
- Published
- 1999
13. Health law and ethics. Ethics instruction at schools of public health in the United States.
- Author
-
Coughlin SS, Katz WH, and Mattison DR
- Abstract
OBJECTIVES: A survey of US schools of public health was undertaken in 1996 and 1997 to obtain a general picture of public health ethics curricula. METHODS: An explanatory letter with a list of questions for discussion was sent to the deans of the accredited US schools of public health. The deans were asked that at least 1 individual at their school who 'is most knowledgeable about ethics curricula' review the list of questions and complete an ethics survey contact form. RESULTS: Ethics instruction was required for all students at only 1 (4%) of the 24 schools surveyed, while 7 schools required ethics instruction for some students. Two of the schools had no ethics courses. Ethics instruction was required for all MPH students at 9 (38%) of the schools and for all doctoral students at 4 (17%) of the schools. Most of the schools (19 of 24, or 79%) offered short courses, seminar series, or invited lectures on ethical topics, and 23 (96%) included lectures on ethics topics in other courses such as health law. CONCLUSIONS: Training programs at US schools of public health vary greatly in how much attention is given to ethics instruction. Model curricula in public health ethics should be developed to help fill this gap. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
14. Making progress for how medicines are used in children.
- Author
-
Taylor-Zapata P and Mattison DR
- Published
- 2007
- Full Text
- View/download PDF
15. Analgesics for the treatment of pain in children.
- Author
-
Birenbaum D, Mattison DR, Berde C, and Sethna N
- Published
- 2003
16. Folic acid requirements for women of childbearing age.
- Author
-
Mattison DR
- Published
- 1999
17. Newborn drug development initiative: improving neonatal therapeutics. Newborn Drug Development Initiative Workshop, March 29-30, 2004, Baltimore, MD.
- Author
-
Giacoia GP, Birenbaum DL, Sachs HC, and Mattison DR
- Published
- 2006
- Full Text
- View/download PDF
18. IOM on core functions.
- Author
-
Shine KI and Mattison DR
- Published
- 1999
19. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD.
- Author
-
Witt KL, Shelby MD, Itchon-Ramos N, Faircloth M, Kissling GE, Chrisman AK, Ravi H, Murli H, Mattison DR, Kollins SH, Witt, Kristine L, Shelby, Michael D, Itchon-Ramos, Nilda, Faircloth, Melissa, Kissling, Grace E, Chrisman, Allan K, Ravi, Hima, Murli, Hemalatha, Mattison, Donald R, and Kollins, Scott H
- Abstract
Objective: In response to previously published findings of methylphenidate-induced chromosomal changes in children, this study was designed to determine whether methylphenidate- or amphetamine-based drugs induce chromosomal damage (structural aberrations, micronuclei, and sister chromatid exchanges) in peripheral blood lymphocytes of children with attention-deficit/hyperactivity disorder after 3 months of continuous treatment.Method: Stimulant drug-naïve subjects, 6 to 12 years of age, in good overall health, and judged to be appropriate candidates for stimulant therapy based on rigorously diagnosed ADHD using DSM-IV criteria, were randomized into two open-label treatment groups (methylphenidate or mixed amphetamine salts). Each subject provided a blood sample before initiation of treatment and after 3 months of treatment. Pretreatment and posttreatment frequencies of chromosomal aberrations, micronuclei, and sister chromatid exchanges were determined for each subject.Results: Sixty-three subjects enrolled in the study; 47 subjects completed the full 3 months of treatment, 25 in the methylphenidate group and 22 in the amphetamine group. No significant treatment-related increases were observed in any of the three measures of cytogenetic damage in the 47 subjects who completed treatment or the 16 subjects who did not.Conclusions: Earlier findings of methylphenidate-induced chromosomal changes in children were not replicated in this study. These results add to the accumulating evidence that therapeutic levels of methylphenidate do not induce cytogenetic damage in humans. Furthermore, our results indicate that amphetamine-based products do not pose a risk for cytogenetic damage in children. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
20. Non-Ergot Dopamine Agonists and the Risk of Heart Failure and Other Adverse Cardiovascular Reactions in Parkinson's Disease.
- Author
-
Crispo JAG, Farhat N, Fortin Y, Perez-Lloret S, Sikora L, Morgan RL, Habash M, Gogna P, Kelly SE, Elliott J, Kohen DE, Bjerre LM, Mattison DR, Hessian RC, Willis AW, and Krewski D
- Abstract
Reports suggest possible risks of adverse cardiovascular reactions, including heart failure, associated with non-ergot dopamine agonist (DA) use in Parkinson's disease (PD). The objectives of our review were to evaluate the risk of heart failure and other adverse cardiovascular reactions in PD patients who received a non-ergot DA compared with other anti-PD pharmacological interventions, placebo, or no intervention. Studies were identified via searches of six bibliographic databases. Randomized controlled trials (RCTs) and non-randomized studies (NRS) were eligible for study inclusion. Random-effect meta-analyses were performed to estimate adverse cardiovascular reaction risks. Quality of evidence was assessed using GRADE. In total, forty-four studies (thirty-six RCTs and eight NRS) satisfied our inclusion criteria. A single RCT found no significant difference in the risk of heart failure with ropinirole compared with bromocriptine (odds ratio (OR) 0.39, 95% confidence interval (CI) 0.07 to 2.04; low certainty). Conversely, three case-control studies reported a risk of heart failure with non-ergot DA treatment. The quality of evidence for the risk of heart failure was judged as low or very low. Findings suggest that non-ergot DA use may be associated with adverse cardiovascular outcomes, including heart failure. Studies are needed to better understand cardiovascular risks associated with PD treatment.
- Published
- 2024
- Full Text
- View/download PDF
21. Diagnosis of manganism and manganese neurotoxicity: A workshop report.
- Author
-
Mattison DR, Momoli F, Alyanak C, Aschner M, Baker M, Cashman N, Dydak U, Farhat N, Guilarte TR, Karyakina N, Ramoju S, Shilnikova N, Taba P, and Krewski D
- Abstract
With declining exposures to manganese (Mn) in occupational settings, there is a need for more sensitive exposure assessments and clinical diagnostic criteria for manganism and Mn neurotoxicity. To address this issue, a workshop was held on November 12-13, 2020, with international experts on Mn toxicity. The workshop discussions focused on the history of the diagnostic criteria for manganism, including those developed by the Institut de Recherche Robert-Sauvé en Santé et en Sécurité du Travail (IRSST) in Quebec in 2005 and criteria developed by the Chinese government in 2002 and updated in 2006; the utility of biomarkers of exposure; recent developments in magnetic resonance imaging (MRI) for assessing Mn accumulation in the brain and diagnosing manganism; and potential future applications of metabolomics. The suggestions of the participants for updating manganism diagnostic criteria included the consideration of: i) A history of previous occupational and environmental exposure to Mn; ii) relevant clinical symptoms such as dystonia; iii) MRI imaging to document Mn accumulation in the neural tissues, including the basal ganglia; and iv) criteria for the differential diagnosis of manganism and other neurological conditions. Important research gaps include the characterization of Mn exposure and other co-exposures, exploration of the roles of different brain regions with MRI, understanding the complexity of metal ion transporters involved in Mn homeostasis, and a need for information on other neurotransmitter systems and brain regions underlying the pathophysiology of manganism., Competing Interests: MB and UD have received funding from the International Manganese Institute (IMnI). DK is the Natural Sciences and Engineering Research Council of Canada Chair in Risk Science at the University of Ottawa. CA, DK, DM, FM, NK, NS and SR are affiliated with Risk Sciences International (www.risksciences.com), a Canadian company established in 2006 in partnership with the University of Ottawa. RSI has provided consulting services on manganese to public and private sector clients. Although IMnI contributed funding, they did not actively participate in the planning of the workshop or in the development of the workshop report. The workshop deliberations summarized in this report represent the independent views of the authors alone., (Copyright: © Mattison et al.)
- Published
- 2024
- Full Text
- View/download PDF
22. Concomitant use of statins and sodium-glucose co-transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis.
- Author
-
Gravel CA, Krewski D, Mattison DR, Momoli F, and Douros A
- Subjects
- Humans, Myotoxicity, Rosuvastatin Calcium, Adverse Drug Reaction Reporting Systems, Glucose, Sodium, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Muscular Diseases chemically induced, Muscular Diseases epidemiology, Rhabdomyolysis chemically induced, Rhabdomyolysis epidemiology, Symporters
- Abstract
Aims: Recent case reports have suggested that sodium-glucose co-transporter 2 (SGLT2) inhibitors may interact with statins to increase their risk of myotoxicity. We assessed the risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins., Methods: We queried the US Food and Drug Administration Adverse Event Reporting System (FAERS) from 2013 to 2021 for reports including SGLT2 inhibitors, statins or both. We estimated several measures of disproportionate reporting of myopathy and rhabdomyolysis associated with concomitant use of SGLT2 inhibitors and statins: reporting odds ratio (ROR) with 95% confidence interval (CI), Ω shrinkage measure (safety signal if >0) and an extension of the proportional reporting ratio (PRR) (two-criteria set, safety signal if both criteria are met), using the full FAERS dataset as the reference set. In sensitivity analyses, we focussed on specific SGLT2 inhibitor-statin pairs with higher interaction potential (canagliflozin-rosuvastatin, empagliflozin-rosuvastatin) and accounted for stimulated reporting., Results: There were 456 myopathy and 77 rhabdomyolysis reports involving both an SGLT2 inhibitor and a statin. Concomitant use of SGLT2 inhibitors and statins was not associated with an increased risk of myopathy (ROR 0.79, 95% CI 0.70 to 0.89) or rhabdomyolysis (ROR 0.58, 95% CI 0.41 to 0.83) reporting. For both outcomes, the Ω shrinkage measure was negative and only one criterion of the PRR extension was met. SGLT2 inhibitor-statin pairs with higher interaction potential yielded potential signals for rhabdomyolysis; these signals disappeared after accounting for stimulated reporting., Conclusion: There was no increased risk of myotoxicity reporting associated with concomitant use of SGLT2 inhibitors and statins or for specific drug pairs., (© 2023 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)
- Published
- 2023
- Full Text
- View/download PDF
23. Commentary: Systematic reviews and observational epidemiology: The more things change….
- Author
-
LaKind JS, Burns CJ, and Mattison DR
- Published
- 2022
- Full Text
- View/download PDF
24. Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.
- Author
-
Moore TJ, Alami A, Alexander GC, and Mattison DR
- Subjects
- Animals, Humans, Mammals, N-Methylaspartate, Phencyclidine pharmacology, Depression drug therapy, Ketamine adverse effects, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors
- Abstract
Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders. At subanesthetic doses, the two drugs, along with their older congener, phencyclidine (PCP), induce a transient, altered mental state by blocking the N-methyl-D-aspartate (NMDA) receptor for glutamate, the primary excitatory neurotransmitter in the mammalian central nervous system. This multidisciplinary review examines the pharmacology/direct effects on consciousness, effectiveness in depression and acute suicidality, and safety of these fast-acting NMDA antagonists. To capture the essence of 60 years of peer-reviewed literature, we used a semi-structured approach to the subtopics, each of which required a different search strategy. We review the evidence for the three primary reported benefits of the two clinical drugs when used for depression: success in difficult-to-treat patients, rapid onset of action within a day, and immediate effects on suicidality. Key safety issues include the evidence-and lack thereof-for the effects of repeatedly inducing this altered mental state, and whether an adequate safety margin exists to rule out the neurotoxic effects seen in animal studies. This review includes evidence from multiple sources that raise substantial questions about both safety and effectiveness of ketamine and esketamine for psychiatric disorders., (© 2022 The Authors. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy published by Wiley Periodicals LLC on behalf of Pharmacotherapy Publications, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
25. Systemic quinolones and risk of acute liver failure I: Analysis of data from the US FDA adverse event reporting system.
- Author
-
Taher MK, Alami A, Gravel CA, Tsui D, Bjerre LM, Momoli F, Mattison DR, and Krewski D
- Abstract
Background and Aim: Quinolones are a potent and globally popular group of antibiotics that are used to treat a wide range of infections. Some case reports have raised concern about their possible association with acute hepatic failure (AHF). Data from the US FDA Adverse Event Reporting System were evaluated for signals of AHF in association with systemically administered quinolone antibiotics., Methods: AHF reports between 1969 and 2019q2, with a focus on 2010-2019q2, were analyzed. Specifically, AHF reports linked to non-quinolone antibiotics of known hepatotoxicity were compared to reports with non-quinolone, non-hepatotoxic (reference) antibiotics; and AHF reports with quinolones were also compared to reports with the same group of reference antibiotics. Two disproportionality signal detection techniques (proportional reporting ratio, PRR, and empirical Bayes geometric mean, EBGM) were used to assess the AHF signal for both analyses., Results: Only ciprofloxacin showed a marginal and significant AHF signal (PRR: 1.85 [1.21, 2.81]; EBGM: 1.54 [1.06, 1.81]); moxifloxacin, levofloxacin, and ofloxacin showed weak and nonsignificant signals., Conclusion: Further pharmacovigilance studies are required to confirm the association between ciprofloxacin and AHF seen in the present analysis., (© 2021 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
26. Concomitant Ceftriaxone and Intravenous Calcium Therapy in Infants.
- Author
-
Christensen ML, Zareie P, Kadiyala B, Bursac Z, Reed MD, Mattison DR, and Davis RL
- Abstract
Objective: To determine if increased mortality could be detected with the administration of ceftriaxone and IV calcium in infants through an analysis of a large repository of electronic health records., Methods: Patients were split into 3 groups: 1) neonates, 2) infants, and 3) infants <1 year whose age was not specified. Deaths were classified into mutually exclusive categories based on the administration and timing of ceftriaxone and IV calcium. Crude death rates were calculated, and logistic regression modeling was used to calculate adjusted relative odds of death with associated covariates., Results: A total of 259,149 infants were identified. Of 79,038 neonates, the proportion of patients that received ceftriaxone and IV calcium within 48 hours who died was 3.8%, compared with 1.95% (IV calcium), 0.3% (ceftriaxone), 1.54% (IV fluids), and 2.03% (parenteral nutrition). For 102,456 infants, the proportions of deaths were 5.47% (ceftriaxone and IV calcium within 48 hours), 0.45% (IV calcium), 0.15% (ceftriaxone), 0.39% (IV fluids), and 5.5% (parenteral nutrition). Multivariate analysis showed increased odds of death in infants who received ceftriaxone and IV calcium within 48 hours, regardless of age, and propensity score-matched analysis showed a more than 2-fold increased risk for death., Conclusions: The increased risk for death following ceftriaxone and IV calcium administration was noted not only in neonates, but among older infants as well., Competing Interests: Disclosures. The authors declare no conflicts or financial interest related to the manuscript., (Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: mhelms@pediatricpharmacy.org 2021.)
- Published
- 2021
- Full Text
- View/download PDF
27. Risk of Adverse Cardiovascular Events Following a Myocardial Infarction in Patients Receiving Combined Clopidogrel and Proton Pump Inhibitor Treatment: A Nested Case-Control Study.
- Author
-
Farhat N, Birkett N, Haddad N, Fortin Y, Momoli F, Wen SW, Wielgosz A, McNair DS, Mattison DR, and Krewski D
- Abstract
Background: The clinical implications of potential interactions between proton pump inhibitors (PPIs) and clopidogrel have been debated for over a decade., Objective: We assessed the association between combined clopidogrel-PPI treatment and the risk of recurrent myocardial infarction (MI) and three secondary outcomes., Patients and Methods: A nested case-control study was conducted within Cerner Corporation's Health Facts
® database. A retrospective cohort of patients who experienced a first MI and started clopidogrel treatment was created. Within this cohort, patients experiencing a second MI (cases) were matched with up to five controls. Logistic regression was used to estimate adjusted odds ratios (aORs). Findings were compared with those obtained from models with three negative control exposure drugs: H2 receptor antagonists, prasugrel, and ticagrelor., Results: In total, 2890 recurrent MI cases were identified within 12 months following entry into the cohort of clopidogrel users (N = 52,006). aOR for PPI use versus non-use among clopidogrel users was 1.08 [95% confidence interval (CI) 0.95-1.23]. Similar ORs were obtained for secondary endpoints. A positive association between combined use of clopidogrel/PPIs and increased risk of MI was seen in the group aged 80-89 years (aOR 1.26; 95% CI 1.05-1.51). No associations with MI were observed for (1) H2 receptor antagonist use versus non-use among clopidogrel users or (2) PPI use versus non-use among prasugrel users or among ticagrelor users., Conclusions: Overall, our findings do not support a significant adverse clinical impact of concomitant clopidogrel/PPI use by patients with MI. Nonetheless, investigation of the possible association seen in those aged 80-89 years may be warranted.- Published
- 2020
- Full Text
- View/download PDF
28. The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use
- Author
-
Jackson LM, Parker RM, and Mattison DR
- Abstract
The U.S. Food and Drug Administration (FDA) has approved dozens of hormone therapy products for men and women, including estrogen, progesterone, testosterone, and related compounds. These products have been reviewed for safety and efficacy and are indicated for treatment of symptoms resulting from hormonal changes associated with menopause or other endocrine-based disorders. In recent decades, an increasing number of health care providers and patients have turned to custom-formulated, or compounded, drug preparations as an alternative to FDA-approved drug products for hormone-related health concerns. These compounded hormone preparations are often marketed as “bioidentical” or “natural” and are commonly referred to as compounded bioidentical hormone therapy (cBHT). In light of the fast-growing popularity of cBHT preparations, the clinical utility of these compounded preparations is a substantial public health concern for various stakeholders, including medical practitioners, patients, health advocacy organizations, and federal and state public health agencies. This report examines the clinical utility and uses of cBHT drug preparations and reviews the available evidence that would support marketing claims of the safety and effectiveness of cBHT preparations. It also assesses whether the available evidence suggests that these preparations have clinical utility and safety profiles warranting their clinical use and identifies patient populations that might benefit from cBHT preparations in lieu of FDA-approved BHT., (Copyright 2020 by the National Academy of Sciences. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
29. Systematic review and meta-analysis of adverse cardiovascular events associated with proton pump inhibitors used alone or in combination with antiplatelet agents.
- Author
-
Farhat N, Fortin Y, Haddad N, Birkett N, Mattison DR, Momoli F, Wu Wen S, and Krewski D
- Subjects
- Cardiovascular Diseases epidemiology, Drug Interactions, Cardiovascular Diseases chemically induced, Platelet Aggregation Inhibitors adverse effects, Proton Pump Inhibitors adverse effects
- Abstract
The potential association between major adverse cardiovascular events (MACE) and concomitant treatment with proton pump inhibitors (PPIs) and clopidogrel has been debated since 2009. Recent reports, however, suggest that PPIs may increase the risk of MACE independently of clopidogrel. This review evaluates epidemiological findings relevant to the association between PPIs, taken alone or concomitantly with antiplatelets, and the risk of MACE. A systematic review and meta-analysis were conducted. Relevant studies were identified from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials and then screened. Included studies were categorized into three groups: Group A: PPIs versus no PPIs; Group B: combined PPIs and clopidogrel versus clopidogrel alone; Group C: combined PPIs and other drugs versus other drugs. Pooled risk ratios (RRs) were calculated for each outcome of interest in each comparison group. Of the 1667 studies identified, 118 were included in the systematic review, of which 66 were included in the meta-analyses. Among Group A observational studies, RRs for MACE outcomes were statistically significant for some patient populations but not others. Pooled RRs from Group A RCTs were not statistically significant for any outcome. Pooled RRs for Group B observational studies were statistically significant for all-cause mortality and MI, but were diminished in magnitude when pooling was restricted to propensity score matched studies or post hoc analyses of RCTs. Group C studies did not demonstrate an association with MACE. Findings do not consistently support an association between MACE and PPIs when taken alone, or concomitantly with antiplatelets.
- Published
- 2019
- Full Text
- View/download PDF
30. Trends in concomitant clopidogrel and proton pump inhibitor treatment among ACS inpatients, 2000-2016.
- Author
-
Farhat N, Haddad N, Crispo J, Birkett N, McNair D, Momoli F, Wen SW, Mattison DR, and Krewski D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Drug Interactions physiology, Drug Therapy, Combination methods, Female, Humans, Inpatients, Male, Middle Aged, Platelet Aggregation Inhibitors therapeutic use, United States, United States Food and Drug Administration, Young Adult, Acute Coronary Syndrome drug therapy, Clopidogrel therapeutic use, Proton Pump Inhibitors therapeutic use
- Abstract
Purpose: The US Food and Drug Administration (FDA) issued three safety announcements between January 2009 and October 2010 warning against concomitant use of clopidogrel and proton pump inhibitors (PPIs) due to a potential drug-drug interaction that may attenuate clopidogrel's antiplatelet activity. This primary objective of this study was to examine trends in concomitant clopidogrel/PPI use among acute coronary syndrome (ACS) inpatients in the US between 2000 and 2016, in relation to the FDA safety communications., Methods: Adult inpatients with a primary diagnosis of ACS were identified from the Cerner Health Facts® database. The standardized (age, sex, race, and census region) prevalence of clopidogrel use with PPIs was calculated yearly and quarterly. Findings were stratified by PPIs' potential to inhibit clopidogrel's activity and by age., Results: A total of 204,533 inpatients were identified. In 2008, the prevalence of concomitant clopidogrel and PPI treatment was 34.9%, decreasing to 24.4 and 16.4% in 2009 and 2010, respectively, with the decline being similar across age groups. Treatment with inhibiting PPIs (omeprazole and esomeprazole) and clopidogrel has continued to decrease since 2010, with a prevalence of 0.8% in 2016. A similar reduction was not observed with clopidogrel and non-inhibiting PPIs (pantoprazole, lansoprazole, rabeprazole, and dexlansoprazole). During the FDA warning period, the combined treatment with clopidogrel and H
2 receptor antagonists, an alternative to PPIs suggested by the FDA, temporarily increased from 7.8% in 2008 to 12.8 and 14.5% in 2009 and 2010, respectively., Conclusions: Findings suggest that clinical practice recommendations made by the FDA were followed. Further research is needed to determine how changes in drug labels and the availability of new drugs may have influenced the observed trends.- Published
- 2019
- Full Text
- View/download PDF
31. Comparative, cross-sectional study of the format, content and timing of medication safety letters issued in Canada, the USA and the UK.
- Author
-
Bjerre LM, Parlow S, de Launay D, Hogel M, Black CD, Mattison DR, Grimshaw JM, and Watson MC
- Subjects
- Canada, Communication, Cross-Sectional Studies, Government Agencies, Humans, Patient Safety, Safety Management, United Kingdom, United States, Correspondence as Topic, Medication Errors prevention & control, Pharmaceutical Preparations
- Abstract
Objectives: To assess consistency in the format and content, and overlap of subject and timing, of medication safety letters issued by regulatory health authorities to healthcare providers in Canada, the USA and the UK., Design: A cross-sectional study comparing medication safety letters issued for the purpose of alerting healthcare providers to newly identified medication problems associated with medications already on the market., Setting: Online databases operated by Health Canada, the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency were searched to select medication safety letters issued between 1 January 2010 and 31 December 2014. Format, content and timing of each medication safety letter were assessed using an abstraction tool comprising 21 characteristics deemed relevant by consensus of the research team., Main Outcome Measures: Main outcome measures included, first, characteristics (format and content) of medication safety letters and second, overlap of subject and release date across countries., Results: Of 330 medication safety letters identified, 227 dealt with unique issues relating to medications available in all three countries. Of these 227 letters, 21 (9%) medication problems were the subject of letters released in all three countries; 40 (18%) in two countries and 166 (73%) in only one country. Only 13 (62%) of the 21 letters issued in all three countries were released within 6 months of each other., Conclusions: Significant discrepancies in both the subject and timing of medication safety letters issued by health authorities in three countries (Canada, the USA and the UK) where medical practice is otherwise comparable, raising questions about why, how and when medication problems are identified and communicated to healthcare providers by the authorities. More rapid communication of medication problems and better alignment between authorities could enhance patient safety., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2018
- Full Text
- View/download PDF
32. Assessment of Patterns of Potentially Unsafe Use of Zolpidem.
- Author
-
Moore TJ and Mattison DR
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Female, GABA-A Receptor Agonists administration & dosage, GABA-A Receptor Agonists adverse effects, Humans, Incidence, Male, Middle Aged, United States epidemiology, Young Adult, Zolpidem administration & dosage, Depression drug therapy, Drug-Related Side Effects and Adverse Reactions epidemiology, Risk Assessment methods, Zolpidem adverse effects
- Published
- 2018
- Full Text
- View/download PDF
33. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.
- Author
-
Davidson MA, Mattison DR, Azoulay L, and Krewski D
- Subjects
- Animals, Cell Proliferation drug effects, Female, Humans, Inflammation drug therapy, Male, Neoplasms drug therapy, Neoplasms prevention & control, Osteogenesis drug effects, Thiazolidinediones adverse effects, Diabetes Mellitus, Type 2 drug therapy, Thiazolidinediones pharmacology, Thiazolidinediones therapeutic use
- Abstract
Thiazolidinedione (TZD) drugs used in the treatment of type 2 diabetes mellitus (T2DM) have proven effective in improving insulin sensitivity, hyperglycemia, and lipid metabolism. Though well tolerated by some patients, their mechanism of action as ligands of peroxisome proliferator-activated receptors (PPARs) results in the activation of several pathways in addition to those responsible for glycemic control and lipid homeostasis. These pathways, which include those related to inflammation, bone formation, and cell proliferation, may lead to adverse health outcomes. As treatment with TZDs has been associated with adverse hepatic, cardiovascular, osteological, and carcinogenic events in some studies, the role of TZDs in the treatment of T2DM continues to be debated. At the same time, new therapeutic roles for TZDs are being investigated, with new forms and isoforms currently in the pre-clinical phase for use in the prevention and treatment of some cancers, inflammatory diseases, and other conditions. The aims of this review are to provide an overview of the mechanism(s) of action of TZDs, a review of their safety for use in the treatment of T2DM, and a perspective on their current and future therapeutic roles.
- Published
- 2018
- Full Text
- View/download PDF
34. External validation and comparison of two variants of the Elixhauser comorbidity measures for all-cause mortality.
- Author
-
Fortin Y, Crispo JA, Cohen D, McNair DS, Mattison DR, and Krewski D
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, International Classification of Diseases, Male, Middle Aged, ROC Curve, Risk Assessment, Young Adult, Comorbidity, Hospital Mortality
- Abstract
Assessing prevalent comorbidities is a common approach in health research for identifying clinical differences between individuals. The objective of this study was to validate and compare the predictive performance of two variants of the Elixhauser comorbidity measures (ECM) for inhospital mortality at index and at 1-year in the Cerner Health Facts® (HF) U.S., Database: We estimated the prevalence of select comorbidities for individuals 18 to 89 years of age who received care at Cerner contributing health facilities between 2002 and 2011 using the AHRQ (version 3.7) and the Quan Enhanced ICD-9-CM ECMs. External validation of the ECMs was assessed with measures of discrimination [c-statistics], calibration [Hosmer-Lemeshow goodness-of-fit test, Brier Score, calibration curves], added predictive ability [Net Reclassification Improvement], and overall model performance [R2]. Of 3,273,298 patients with a mean age of 43.9 years and a female composition of 53.8%, 1.0% died during their index encounter and 1.5% were deceased at 1-year. Calibration measures were equivalent between the two ECMs. Calibration performance was acceptable when predicting inhospital mortality at index, although recalibration is recommended for predicting inhospital mortality at 1 year. Discrimination was marginally better with the Quan ECM compared the AHRQ ECM when predicting inhospital mortality at index (cQuan = 0.887, 95% CI: 0.885-0.889 vs. cAHRQ = 0.880, 95% CI: 0.878-0.882; p < .0001) and at 1-year (cQuan = 0.884, 95% CI: 0.883-0.886 vs. cAHRQ = 0.880, 95% CI: 0.878-0.881, p < .0001). Both the Quan and the AHRQ ECMs demonstrated excellent discrimination for inhospital mortality of all-causes in Cerner Health Facts®, a HIPAA compliant observational research and privacy-protected data warehouse. While differences in discrimination performance between the ECMs were statistically significant, they are not likely clinically meaningful.
- Published
- 2017
- Full Text
- View/download PDF
35. Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race.
- Author
-
Moore TJ and Mattison DR
- Subjects
- Adult, Age Factors, Female, Humans, Male, Mental Disorders epidemiology, Middle Aged, Morbidity, Sex Factors, United States epidemiology, Drug Utilization statistics & numerical data, Mental Disorders drug therapy, Psychotropic Drugs pharmacology, Racial Groups
- Published
- 2017
- Full Text
- View/download PDF
36. Manganese showcase symposium.
- Author
-
Mattison DR, Levy L, and McGough D
- Published
- 2017
- Full Text
- View/download PDF
37. The application of PBPK models in estimating human brain tissue manganese concentrations.
- Author
-
Ramoju SP, Mattison DR, Milton B, McGough D, Shilnikova N, Clewell HJ, Yoon M, Taylor MD, Krewski D, and Andersen ME
- Subjects
- Dose-Response Relationship, Drug, Humans, Models, Biological, Regression Analysis, Brain metabolism, Manganese metabolism, Manganese pharmacokinetics, Manganese toxicity, Manganese Poisoning pathology, Occupational Exposure
- Abstract
Mn is an essential element that causes neurotoxicity in humans when inhaled at high concentrations. This metal has well-recognized route-dependent differences in absorption, with greater proportionate uptake for inhalation versus dietary exposure. Physiologically-based pharmacokinetic (PBPK) models for Mn have included these route specific differences in uptake and their effect on delivery of Mn to target tissues via systemic circulation. These PBPK models include components describing ingestion and inhalation, homeostatic control (concentration dependent biliary elimination and gastrointestinal absorption), and delivery to target sites within the brain. The objective of this study was to combine PBPK modeling of target tissue Mn concentration and categorical regression analysis to identify Mn intake levels (both by food and air) that are expected to cause minimal toxicity. We first used the human PBPK model to describe blood Mn data from three occupational exposure studies, demonstrating consistency between model predictions and measured data. The PBPK model was then used to predict concentrations of Mn in the globus pallidus (the presumed target tissue for motor function disruption in humans) for various epidemiological studies. With the predicted globus pallidus concentration of Mn, we conducted categorical regression modeling between globus pallidus Mn and severity-scored neurological outcome data from the human cohorts. This structured tissue dose - response analysis led to an estimated 10% extra risk concentration (ERC
10 ) of 0.55μg/g Mn in the globus pallidus, which is comparable to similar values estimated by the Agency of Toxic Substances and Disease Registry and Health Canada (after translation from external exposure to tissue dose). The steep dose-response curve below this ERC10 value may be used to inform the choice of adjustment factor to translate the ERC10 as a point of departure to a reference concentration for occupational or environmental exposure to Mn. Because these results are based on human epidemiological data and a human PBPK model, adjustment or translation of results from animals to humans is not required., (Copyright © 2016 Elsevier B.V. All rights reserved.)- Published
- 2017
- Full Text
- View/download PDF
38. Modeling U-shaped dose-response curves for manganese using categorical regression.
- Author
-
Milton B, Krewski D, Mattison DR, Karyakina NA, Ramoju S, Shilnikova N, Birkett N, Farrell PJ, and McGough D
- Subjects
- Animals, Databases, Bibliographic statistics & numerical data, Disease Models, Animal, Dose-Response Relationship, Drug, Rats, Logistic Models, Manganese toxicity, Manganese Poisoning etiology
- Abstract
Introduction: Manganese is an essential nutrient which can cause adverse effects if ingested to excess or in insufficient amounts, leading to a U-shaped exposure-response relationship. Methods have recently been developed to describe such relationships by simultaneously modeling the exposure-response curves for excess and deficiency. These methods incorporate information from studies with diverse adverse health outcomes within the same analysis by assigning severity scores to achieve a common response metric for exposure-response modeling., Objective: We aimed to provide an estimate of the optimal dietary intake of manganese to balance adverse effects from deficient or excess intake., Methods: We undertook a systematic review of the literature from 1930 to 2013 and extracted information on adverse effects from manganese deficiency and excess to create a database on manganese toxicity following oral exposure. Although data were available for seven different species, only the data from rats was sufficiently comprehensive to support analytical modelling. The toxicological outcomes were standardized on an 18-point severity scale, allowing for a common analysis of all available toxicological data. Logistic regression modelling was used to simultaneously estimate the exposure-response profile for dietary deficiency and excess for manganese and generate a U-shaped exposure-response curve for all outcomes., Results: Data were available on the adverse effects of 6113 rats. The nadir of the U-shaped joint response curve occurred at a manganese intake of 2.70mg/kgbw/day with a 95% confidence interval of 2.51-3.02. The extremes of both deficient and excess intake were associated with a 90% probability of some measurable adverse event., Conclusion: The manganese database supports estimation of optimal intake based on combining information on adverse effects from systematic review of published experiments. There is a need for more studies on humans. Translation of our results from rats to humans will require adjustment for interspecies differences in sensitivity to manganese., (Copyright © 2016 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
39. Severity scoring of manganese health effects for categorical regression.
- Author
-
Mattison DR, Milton B, Krewski D, Levy L, Dorman DC, Aggett PJ, Roels HA, Andersen ME, Karyakina NA, Shilnikova N, Ramoju S, and McGough D
- Subjects
- Animals, Copper toxicity, Databases, Factual, Dose-Response Relationship, Drug, Environmental Exposure, Female, Humans, Male, Manganese toxicity, Manganese Poisoning etiology, Regression Analysis
- Abstract
Characterizing the U-shaped exposure response relationship for manganese (Mn) is necessary for estimating the risk of adverse health from Mn toxicity due to excess or deficiency. Categorical regression has emerged as a powerful tool for exposure-response analysis because of its ability to synthesize relevant information across multiple studies and species into a single integrated analysis of all relevant data. This paper documents the development of a database on Mn toxicity designed to support the application of categorical regression techniques. Specifically, we describe (i) the conduct of a systematic search of the literature on Mn toxicity to gather data appropriate for dose-response assessment; (ii) the establishment of inclusion/exclusion criteria for data to be included in the categorical regression modeling database; (iii) the development of a categorical severity scoring matrix for Mn health effects to permit the inclusion of diverse health outcomes in a single categorical regression analysis using the severity score as the outcome variable; and (iv) the convening of an international expert panel to both review the severity scoring matrix and assign severity scores to health outcomes observed in studies (including case reports, epidemiological investigations, and in vivo experimental studies) selected for inclusion in the categorical regression database. Exposure information including route, concentration, duration, health endpoint(s), and characteristics of the exposed population was abstracted from included studies and stored in a computerized manganese database (MnDB), providing a comprehensive repository of exposure-response information with the ability to support categorical regression modeling of oral exposure data., (Copyright © 2016 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
40. Demonstration of early efficacy results of the delayed-release combination of doxylamine-pyridoxine for the treatment of nausea and vomiting of pregnancy.
- Author
-
Koren G, Clark S, Hankins GD, Caritis SN, Umans JG, Miodovnik M, Mattison DR, and Matok I
- Subjects
- Antiemetics administration & dosage, Delayed-Action Preparations, Dicyclomine administration & dosage, Doxylamine administration & dosage, Drug Combinations, Female, Humans, Pregnancy, Pyridoxine administration & dosage, Time Factors, Antiemetics therapeutic use, Dicyclomine therapeutic use, Doxylamine therapeutic use, Morning Sickness drug therapy, Pyridoxine therapeutic use
- Abstract
Background: Nausea and vomiting of pregnancy (NVP) affects up to 80% of expecting mothers. In April 2013 the FDA approved the delayed-release combination of doxylamine succinate and pyridoxine hydrochloride (Diclegis®) for NVP, based in part, on the results of a phase III randomized trial demonstrating the efficacy of this drug combination [study drug marketed under the trade name Diclectin® in Canada and Diclegis® in the United States] compared to placebo in pregnant women. Study drug dosing occurred for 14 days, which is substantially longer than what has been performed in similar studies. The objective of this study was to evaluate, through secondary analysis, whether the primary measure of efficacy can be demonstrated after five days of treatment., Methods: Women suffering from NVP were randomized to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from two to four tablets a day, based on a pre-specified titration protocol. The primary efficacy endpoint was the change in the validated Pregnancy-Unique Quantification of Emesis (PUQE) score at baseline versus Day 15 between Diclegis®-treated and placebo-treated women. For the present study, the change in PUQE score between baseline and Day 15 (end of the study) was compared to the changes observed for Days 3, 4, and 5., Results: The use of delayed-release doxylamine succinate and pyridoxine hydrochloride tablets show improved NVP symptom control as compared to placebo on Days 3,4 and 5, with sustained efficacy until the end of the trial., Conclusion: A four day study drug dosing trial with Diclegis® is sufficient to document efficacy, as the results are similar to those achieved after 14 study drug dosing days. The benefit seen at the earlier time validates drug efficacy and minimizes the natural course of improvement., Trial Registration: CTR No. NCT006 14445 2007.
- Published
- 2016
- Full Text
- View/download PDF
41. Completeness of serious adverse drug event reports received by the US Food and Drug Administration in 2014.
- Author
-
Moore TJ, Furberg CD, Mattison DR, and Cohen MR
- Subjects
- Humans, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems standards, Drug Industry, Drug-Related Side Effects and Adverse Reactions epidemiology
- Abstract
Purpose: Adverse drug event reports to the US Food and Drug Administration (FDA) remain the primary tool for identifying serious drug adverse effects without adequate existing warnings. We assessed the completeness of reports the FDA received in 2014., Methods: Serious adverse drug event reports were evaluated for whether they included age, gender, event date, and at least one medical term describing the event in computer excerpts. Report sources were direct reports to the FDA, manufacturer expedited reports about events without adequate warnings, and manufacturer periodic reports about events with existing warnings., Results: In 2014, the FDA received 528,192 new case reports indicating a serious or fatal outcome, 25,038 (4.7%) directly from health professionals and consumers, and 503,154 (95.3%) from drug manufacturers. Overall, 21,595 (86.2%) of serious reports submitted directly to the FDA provided data for all four completeness variables, compared with 271,022 (40.4%) of manufacturer expedited reports and 24,988 (51.3%) of periodic reports. Among manufacturer serious reports, 37.9% lacked age and 46.9% had no event date. Performance by 25 manufacturers submitting 5000 or more reports varied from 24.4% complete on all variables to 67% complete. Patient death cases had the lowest completeness scores in all categories., Conclusions: By these measures, report completeness from drug manufacturers was poor compared with direct submissions to the agency. The FDA needs to update reporting requirements and compliance policies to help industry capture better adverse event information from new forms of manufacturer interactions with health professionals and consumers. Copyright © 2016 John Wiley & Sons, Ltd., (Copyright © 2016 John Wiley & Sons, Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
42. Effectiveness of doxylamine-pyridoxine for morning sickness.
- Author
-
Koren G, Hankins GD, Clark S, Caritis SN, Miodovnik M, Umans JG, and Mattison DR
- Subjects
- Delayed-Action Preparations, Dicyclomine administration & dosage, Doxylamine administration & dosage, Drug Combinations, Female, Humans, Pregnancy, Pyridoxine administration & dosage, Dicyclomine therapeutic use, Doxylamine therapeutic use, Morning Sickness drug therapy, Pyridoxine therapeutic use
- Published
- 2016
- Full Text
- View/download PDF
43. Associations between Anticholinergic Burden and Adverse Health Outcomes in Parkinson Disease.
- Author
-
Crispo JA, Willis AW, Thibault DP, Fortin Y, Hays HD, McNair DS, Bjerre LM, Kohen DE, Perez-Lloret S, Mattison DR, and Krewski D
- Subjects
- Accidental Falls prevention & control, Adult, Aged, Aged, 80 and over, Cognition Disorders chemically induced, Cognition Disorders complications, Cohort Studies, Databases, Factual, Delirium chemically induced, Delirium complications, Emergency Service, Hospital, Female, Fractures, Bone complications, Fractures, Bone prevention & control, Hospitalization, Humans, Inpatients, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Risk Factors, Treatment Outcome, Cholinergic Antagonists adverse effects, Parkinson Disease complications, Parkinson Disease therapy
- Abstract
Background: Elderly adults should avoid medications with anticholinergic effects since they may increase the risk of adverse events, including falls, delirium, and cognitive impairment. However, data on anticholinergic burden are limited in subpopulations, such as individuals with Parkinson disease (PD). The objective of this study was to determine whether anticholinergic burden was associated with adverse outcomes in a PD inpatient population., Methods: Using the Cerner Health Facts® database, we retrospectively examined anticholinergic medication use, diagnoses, and hospital revisits within a cohort of 16,302 PD inpatients admitted to a Cerner hospital between 2000 and 2011. Anticholinergic burden was computed using the Anticholinergic Risk Scale (ARS). Primary outcomes were associations between ARS score and diagnosis of fracture and delirium. Secondary outcomes included associations between ARS score and 30-day hospital revisits., Results: Many individuals (57.8%) were prescribed non-PD medications with moderate to very strong anticholinergic potential. Individuals with the greatest ARS score (≥ 4) were more likely to be diagnosed with fractures (adjusted odds ratio (AOR): 1.56, 95% CI: 1.29-1.88) and delirium (AOR: 1.61, 95% CI: 1.08-2.40) relative to those with no anticholinergic burden. Similarly, inpatients with the greatest ARS score were more likely to visit the emergency department (adjusted hazard ratio (AHR): 1.32, 95% CI: 1.10-1.58) and be readmitted (AHR: 1.16, 95% CI: 1.01-1.33) within 30-days of discharge., Conclusions: We found a positive association between increased anticholinergic burden and adverse outcomes among individuals with PD. Additional pharmacovigilance studies are needed to better understand risks associated with anticholinergic medication use in PD.
- Published
- 2016
- Full Text
- View/download PDF
44. Off-label use of cancer therapies in women diagnosed with breast cancer in the United States.
- Author
-
Hamel S, McNair DS, Birkett NJ, Mattison DR, Krantis A, and Krewski D
- Abstract
Purpose: To determine the level of off-label cancer therapy use in a population of female breast cancer patients and to establish whether this use was evidence-based., Methods: A study was conducted by sampling Cerner's data warehouse for all women diagnosed with breast cancer between January 2000 and June 2009 who received at least one cancer therapy approved by the US-FDA during the study period. Drug encounters were considered off-label if the circumstances of use did not match the age or medical diagnoses specified on the product label at the time of study. The level of evidence for the use of these drugs in a breast cancer setting was evaluated from randomized phase III trials using a tiered approach., Results: The study included 2,663 women with a median age of 59 years. A total of 1,636 off-label encounters were recorded, representing 13.0% of all encounters. Of the 65 cancer therapies investigated, 55.4% were prescribed off-label. The drugs with the highest off-label use were, in a descending order, vinorelbine, carboplatin, bevacizumab, leuprolide, liposomal doxorubicin and cisplatin. Most off-label encounters were evidence-based and more likely to be associated with private insurance coverage, younger age, ethnicities other than Caucasian, smaller treatment centres and drugs with limited labeled indications that have a longer market history., Conclusions: Off-label prescribing is common practice in oncology and is an integral component of breast cancer treatment strategies. While this practice tends to be associated with specific socio-demographic factors and disease characteristics, the majority of off-label encounters appear to be evidence-based.
- Published
- 2015
- Full Text
- View/download PDF
45. Maternal safety of the delayed-release doxylamine and pyridoxine combination for nausea and vomiting of pregnancy; a randomized placebo controlled trial.
- Author
-
Koren G, Clark S, Hankins GD, Caritis SN, Umans JG, Miodovnik M, Mattison DR, and Matok I
- Subjects
- Adult, Antiemetics administration & dosage, Antiemetics adverse effects, Delayed-Action Preparations administration & dosage, Delayed-Action Preparations adverse effects, Double-Blind Method, Drug Combinations, Drug Monitoring methods, Female, Histamine H1 Antagonists administration & dosage, Histamine H1 Antagonists adverse effects, Humans, Pregnancy, Treatment Outcome, Vitamin B Complex, Dicyclomine administration & dosage, Dicyclomine adverse effects, Doxylamine administration & dosage, Doxylamine adverse effects, Nausea drug therapy, Nausea etiology, Pregnancy Complications drug therapy, Pyridoxine administration & dosage, Pyridoxine adverse effects, Vomiting drug therapy, Vomiting etiology
- Abstract
Background: Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting up to 80% of expecting mothers. In April 2013 the FDA approved the delayed release combination of doxylamine succinate and -pyridoxine hydrochloride (Diclegis®) for NVP, following a phase 3 randomized trial in pregnant women. The fetal safety of this medication has been proven by numerous studies. However, because it is the only FDA-approved medication for NVP that is likely to be used by a large number of pregnant women, its maternal safety is an important public health question. The Objective is to evaluate the maternal safety of doxylamine succinate -pyridoxine hydrochloride delayed-release preparation (Diclegis® as compared to placebo., Methods: We randomized women suffering from NVP to receive Diclegis® (n = 131) or placebo (n = 125) for 14 days at doses ranging from 2-4 tablets a day, based on a pre-specified titration protocol response to symptoms. Adverse events were collected through patient diaries, clinical examination and laboratory testing., Results: Doxylamine succinate 10 mg and pyridoxine hydrochloride 10 mg use was not associated with an increased rate of any adverse event over placebo, including CNS depression, gastrointestinal or cardiovascular involvement., Conclusions: Doxylamine succinate-pyridoxine hydrochloride delayed release combination is safe and well tolerated by pregnant women when used in the recommended dose of up to 4 tablets daily in treating nausea and vomiting of pregnancy., Trial Registration: Clinical Trial Registration No: NCT00614445 .
- Published
- 2015
- Full Text
- View/download PDF
46. Improving Concordance in Environmental Epidemiology: A Three-Part Proposal.
- Author
-
LaKind JS, Goodman M, Makris SL, and Mattison DR
- Subjects
- Environmental Health, Guidelines as Topic, Humans, Policy Making, Public Health, Decision Making, Environmental Exposure adverse effects, Epidemiologic Research Design
- Abstract
In observational research, evidence is usually derived from multiple studies, and any single result is rarely considered sufficient for public health decision making. Despite more than five decades of research and thousands of studies published, the ability to draw robust conclusions regarding the presence or absence of causal links between specific environmental exposures and human health remains limited. To develop policies that are protective of public health and can withstand scrutiny, agencies need to rely on investigations of satisfactory quality that follow sufficiently concordant protocols in terms of exposure assessment, outcome ascertainment, data analysis, and reporting of results. Absent such concordance, the ability of environmental epidemiology studies to inform decision making is greatly diminished. Systems and tools are proposed here to improve concordance among environmental epidemiology studies. Specifically, working systems in place in other fields of research are critically examined and used as guidelines to develop analogous policies and procedures for environmental epidemiology. A three-part path forward toward more concordant, transparent, and readily accessible environmental epidemiology evidence that parallels ongoing efforts in medical research is proposed. The three parts address methods for improving quality and accessibility of systematic reviews, access to information on ongoing and completed studies, and principles for reporting. The goals are to increase the value of epidemiological research in public health decision making and to stimulate discussions around solutions proposed herein.
- Published
- 2015
- Full Text
- View/download PDF
47. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs.
- Author
-
Moore TJ, Glenmullen J, and Mattison DR
- Subjects
- Adult, Aged, Aripiprazole, Benzothiazoles adverse effects, Dopamine Agonists administration & dosage, Drug Labeling, Female, Humans, Hyperprolactinemia drug therapy, Impulsive Behavior drug effects, Indoles adverse effects, Male, Middle Aged, Parkinson Disease drug therapy, Piperazines adverse effects, Pramipexole, Quinolones adverse effects, Restless Legs Syndrome drug therapy, Retrospective Studies, United States, United States Food and Drug Administration, Compulsive Behavior chemically induced, Consumer Behavior, Dopamine Agonists adverse effects, Gambling chemically induced, Receptors, Dopamine D3 agonists, Sexual Behavior drug effects
- Abstract
Importance: Severe impulse control disorders involving pathological gambling, hypersexuality, and compulsive shopping have been reported in association with the use of dopamine receptor agonist drugs in case series and retrospective patient surveys. These agents are used to treat Parkinson disease, restless leg syndrome, and hyperprolactinemia., Objectives: To analyze serious adverse drug event reports about these impulse control disorders received by the US Food and Drug Administration (FDA) and to assess the relationship of these case reports with the 6 FDA-approved dopamine receptor agonist drugs., Design, Setting, and Participants: We conducted a retrospective disproportionality analysis based on the 2.7 million serious domestic and foreign adverse drug event reports from 2003 to 2012 extracted from the FDA Adverse Event Reporting System., Main Outcomes and Measures: Cases were selected if they contained any of 10 preferred terms in the Medical Dictionary for Regulatory Activities (MedDRA) that described the abnormal behaviors. We used the proportional reporting ratio (PRR) to compare the proportion of target events to all serious events for the study drugs with a similar proportion for all other drugs., Results: We identified 1580 events indicating impulse control disorders from the United States and 21 other countries:710 fordopamine receptor agonist drugs and 870 for other drugs. The dopamine receptor agonist drugs had a strong signal associated with these impulse control disorders (n = 710; PRR = 277.6, P < .001). The association was strongest for the dopamine agonists pramipexole (n = 410; PRR = 455.9, P < .001) and ropinirole (n = 188; PRR = 152.5, P < .001), with preferential affinity for the dopamine D3 receptor. A signal was also seen for aripiprazole, an antipsychotic classified as a partial agonist of the D3 receptor (n = 37; PRR = 8.6, P < .001)., Conclusions and Relevance: Our findings confirm and extend the evidence that dopamine receptor agonist drugs are associated with these specific impulse control disorders. At present, none of the dopamine receptor agonist drugs approved by the FDA have boxed warnings as part of their prescribing information. Our data, and data from prior studies, show the need for more prominent warnings.
- Published
- 2014
- Full Text
- View/download PDF
48. Studying the antiemetic effect of vitamin B6 for morning sickness: pyridoxine and pyridoxal are prodrugs.
- Author
-
Matok I, Clark S, Caritis S, Miodovnik M, Umans JG, Hankins G, Mattison DR, and Koren G
- Subjects
- Antiemetics blood, Antiemetics pharmacokinetics, Delayed-Action Preparations, Dicyclomine blood, Dicyclomine pharmacokinetics, Double-Blind Method, Doxylamine blood, Doxylamine pharmacokinetics, Drug Combinations, Female, Humans, Morning Sickness metabolism, Pregnancy, Prodrugs pharmacokinetics, Pyridoxal blood, Pyridoxal Phosphate blood, Pyridoxine blood, Pyridoxine pharmacokinetics, Antiemetics therapeutic use, Dicyclomine therapeutic use, Doxylamine therapeutic use, Morning Sickness drug therapy, Prodrugs therapeutic use, Pyridoxine therapeutic use
- Abstract
Vitamin B6 has been known to possess antiemetic effects since 1942. This water soluble compound has several forms in the circulation including pyridoxine, pyridoxal, and pyridoxal phosphate. The active antiemetic form of vitamin B6 is unknown. This was a pre-specified substudy of a randomized, placebo-controlled trial comparing the antiemetic effect of the doxylamine-vitamin B6 combination (Diclectin®) (n = 131) to placebo (n = 126) in women with nausea and vomiting of pregnancy. Serum concentrations of pyridoxine, pyridoxal, and pyridoxal 5' phosphate (PLP) and doxylamine were measured on Days 4, 8, and 15. With Diclectin® exhibiting a significant antiemetic effect in pregnancy, serum concentrations of pyridoxine were unmeasurable in almost all patients and those of pyridoxal were undetectable in half of patients. In contrast, PLP was measurable at sustained, stable steady-state levels in all patients. Our data suggest that there is a correlation between PLP levels and PUQE score of morning sickness symptoms when pyridoxine and pyridoxal levels are undetectable, and hence they might be prodrugs of PLP, which may be the active antiemetic form of vitamin B6., (© 2014, The American College of Clinical Pharmacology.)
- Published
- 2014
- Full Text
- View/download PDF
49. Development of a physiologically based model to describe the pharmacokinetics of methylphenidate in juvenile and adult humans and nonhuman primates.
- Author
-
Yang X, Morris SM, Gearhart JM, Ruark CD, Paule MG, Slikker W Jr, Mattison DR, Vitiello B, Twaddle NC, Doerge DR, Young JF, and Fisher JW
- Subjects
- Adipose Tissue drug effects, Adipose Tissue metabolism, Administration, Oral, Adolescent, Adult, Animals, Biological Availability, Biotransformation, Brain drug effects, Brain metabolism, Central Nervous System Stimulants blood, Child, Gonads drug effects, Gonads metabolism, Humans, Intestine, Small drug effects, Intestine, Small metabolism, Liver drug effects, Liver metabolism, Macaca mulatta, Male, Methylphenidate blood, Models, Biological, Myocardium metabolism, Central Nervous System Stimulants pharmacokinetics, Methylphenidate analogs & derivatives, Methylphenidate pharmacokinetics, Models, Statistical
- Abstract
The widespread usage of methylphenidate (MPH) in the pediatric population has received considerable attention due to its potential effect on child development. For the first time a physiologically based pharmacokinetic (PBPK) model has been developed in juvenile and adult humans and nonhuman primates to quantitatively evaluate species- and age-dependent enantiomer specific pharmacokinetics of MPH and its primary metabolite ritalinic acid. The PBPK model was first calibrated in adult humans using in vitro enzyme kinetic data of MPH enantiomers, together with plasma and urine pharmacokinetic data with MPH in adult humans. Metabolism of MPH in the small intestine was assumed to account for the low oral bioavailability of MPH. Due to lack of information, model development for children and juvenile and adult nonhuman primates primarily relied on intra- and interspecies extrapolation using allometric scaling. The juvenile monkeys appear to metabolize MPH more rapidly than adult monkeys and humans, both adults and children. Model prediction performance is comparable between juvenile monkeys and children, with average root mean squared error values of 4.1 and 2.1, providing scientific basis for interspecies extrapolation of toxicity findings. Model estimated human equivalent doses in children that achieve similar internal dose metrics to those associated with pubertal delays in juvenile monkeys were found to be close to the therapeutic doses of MPH used in pediatric patients. This computational analysis suggests that continued pharmacovigilance assessment is prudent for the safe use of MPH.
- Published
- 2014
- Full Text
- View/download PDF
50. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: a review of the data and identification of knowledge gaps.
- Author
-
Mattison DR, Karyakina N, Goodman M, and LaKind JS
- Subjects
- Animals, Endocrine Disruptors metabolism, Endocrine Disruptors pharmacokinetics, Endocrine Disruptors toxicity, Environmental Exposure adverse effects, Estrogens metabolism, Estrogens pharmacokinetics, Humans, Phytoestrogens pharmacokinetics, Receptors, Estrogen metabolism, Toxicokinetics, Xenobiotics pharmacokinetics, Xenobiotics toxicity, Estrogens toxicity, Phytoestrogens toxicity, Receptors, Estrogen drug effects
- Abstract
Chemicals with estrogenic activity are derived from many different natural and synthetic processes and products, including endogenous production (e.g., estradiol, conjugated estrogens), drugs (e.g., ethinyl estradiol, conjugated estrogens), plants used as foods (phytoestrogens such as genistein, daidzein, S-equol), and man-made chemicals (xenoestrogens such as bisphenol A). Human exposure to low doses of endogenous estrogens, estrogenic drugs, phytoestrogens, and xenoestrogens has the potential to improve health or disrupt normal endocrine activity, as well as impact the diverse systems with which estrogens interact, including the cardiovascular system, and lipid and carbohydrate metabolism. Mechanisms of action and diversity of adverse and non-adverse effects following human exposure to low doses of estrogen active chemicals (EACs, defined as chemicals which interact with an estrogen receptor [ER]) are poorly understood. This review summarizes our current understanding of the pharmacological action with a focus on pharmacokinetics (PK) and toxicokinetics (TK) of several representative EACs in both physiological and pathological processes. The goal of this review is to assess the current state-of-the-science on: (i) the potential for EACs to interfere with endocrine activity, (ii) factors which contribute to endocrine-related clinical outcomes, and (iii) existing knowledge gaps. While classical PK approaches (compartmental or non-compartmental) can be used to characterize absorption, distribution, metabolism, and elimination of EACs, many of the detailed pharmacological characteristics necessary to understand benefit-risk balance have not yet been clarified. Pharmacological complexities mirror the complexity of determining whether and under what conditions exposure to estrogens in drugs, foods or to xenoestrogenic chemicals are beneficial or harmful to human health.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.